# EDGAR Filing Document

**Accession Number:** 0002038166
**File Stem:** 0001213900-26-050128
**Filing Date:** 2026-4
**Character Count:** 132977
**Document Hash:** 9e10c002dfc1cc890060d18fafd119b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-050128.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001213900-26-050128

**CONFORMED SUBMISSION TYPE**: 1-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nok Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002038166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 993344253
- **STATE OF INCORPORATION:** FL

**FILING VALUES:**
- **FORM TYPE:** 1-K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-00991
- **FILM NUMBER:** 26924317

**BUSINESS ADDRESS:**
- **STREET 1:** 1452 N US HIGHWAY 1
- **STREET 2:** STE 123
- **CITY:** ORMOND BEACH
- **STATE:** FL
- **ZIP:** 32174
- **BUSINESS PHONE:** 888-645-3947

**MAIL ADDRESS:**
- **STREET 1:** 1452 N US HIGHWAY 1
- **STREET 2:** STE 123
- **CITY:** ORMOND BEACH
- **STATE:** FL
- **ZIP:** 32174

## Part

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 1-K**

**ANNUAL REPORT PURSUANT TO REGULATION A**

**OF THE SECURITIES ACT OF 1933**

For the Fiscal year ended December 31, 2025

**<u>NOK THERAPEUTICS, INC.</u>**

(Exact name of issuer as specified in its charter)

---

| | |
|:---|:---|
| **Florida** | **99-3344253** |
| (State of other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification Number) |

---

**2009 Mackenzie Way, Suite 100**

**<u>Cranberry Twp, PA 16066</u>**

(Address, including zip code of principal executive office)

**<u>888-691-5839</u>**

(Issuer's telephone number, including area code)

**<u>Class A Common Stock</u>**

(Title of each class of securities issued pursuant to Regulation A)

**Item 1. Business**

NӦK Therapeutics, Inc. ("NӦK" or the "Company") was incorporated on May 22, 2024, in the state of Florida and with its primary place of business located at 2009 Mackenzie Way, Suite 100, Cranberry Twp, PA 16066.

NӦK is a clinical-stage biotechnology company developing Natural Killer (NK) cell-based cancer therapies. These autologous therapies target areas within both hematological malignancies and solid tumors. NK cells play an important role in the body's protection against cancer by effectively recognizing virus-infected and tumor cells. NK cells kill both cell types and also interact with other cells making them vital in innate immune defense.

The NӦK proprietary technology platform and autologous NK cell therapy drug product is designed to target cancer, especially in situations where autologous therapies have a clear benefit over allogeneic therapies. Platform enabling selective expansion and activation of NK cells from cancer patient's peripheral blood produces NK cells with increased tumor killing ability. NӦK's strategy is repeated dosing of long lived autologous re-activated NK cells and achieve tumor targeting by combining with established antibody-dependent cell-mediated cytotoxicity (ADCC) competent monoclonal antibodies (mAbs), exerting their anti-tumor effect by binding to the tumor and recruiting NK cells.

NӦK's hematological malignancy clinical stage pipeline candidate, evencaleucel, has completed first in human Phase I for safety and tolerability in multiple myeloma patients. Treatment with escalating doses of ex vivo activated and expanded NK cells was well tolerated without any severe adverse events. The second hematological candidate, indicated for acute myeloid leukemia (AML), NOK02, along with our two candidates, NOK03 and NOK04 for solid tumors, are in preclinical stages. The rights to develop evencaleucel were acquired during the purchase by NӦK of all assets of XNK from its bankruptcy estate in May 2024.

In May 2024, the Company entered into a patent transfer and assignment agreement with the bankruptcy estate of XNK Therapeutics AB ("XNK"), to purchase key patent families and related intellectual property related to a proprietary technology platform and autologous Natural Killer ("NK") cell therapy drug product.

*Summary of Patent Transfer and Assignment Payments*

● Upfront License fee paid: $150,000;

● All Costs and Revenues, if any, post-closing, to be borne by Buyer (Company).

*Summary of Patent Transfer and Assignment Agreement Terms* 

● Patents sold "as is";

● Seller warrants that the Patents are free and clear of any encumbrance;

● Breach by Seller of Warranties and Covenants:

○ Seller indemnifies the Buyer for loss in excess of $50,000;

○ No individual loss less than $10,000 shall be taken into account;

● Closing date: May 29, 2024.

**Recent Developments**

Recent developments have focused on securing EU manufacturing capacity, culminating in the selection of a Contract Development and Manufacturing Organization (CDMO) with the infrastructure, quality systems, and technical capabilities required to support upcoming human clinical trials

**Our Competitive Advantages**

NÖK Therapeutics' autologous NK cell therapy offers several competitive advantages that position it as a promising option in the field of cancer immunotherapy. First, its autologous nature eliminates the need for a donor, as the therapy uses the patient's own NK cells, reducing the risk of immune rejection and simplifying the logistical challenges associated with donor sourcing, as seen in allogeneic therapies. Second, NÖK's approach does not require lymphodepletion, a strenuous preconditioning process involving chemotherapy drugs like fludarabine and cyclophosphamide, which is commonly used in allogeneic NK cell therapies to prevent graft rejection but can cause significant toxicity and side effects. This absence of lymphodepletion enhances patient safety and tolerability, making the therapy more accessible to those who may not tolerate intensive preconditioning. Third, NK Therapeutics has successfully completed a Phase I clinical trial demonstrating the safety and tolerability of its therapy, a milestone achieved by few autologous NK cell therapy companies, providing a critical foundation for further clinical development and potential market differentiation. Additionally, the therapy's personalized approach allows for tailored treatment that leverages the patient's own immune system, potentially improving efficacy against specific tumor profiles without the risk of graft-versus-host disease (GvHD), a concern in allogeneic settings. The therapy's manufacturing process is also designed to be robust and cost-efficient, as it avoids the need for feeder cells and supports freezing of both starting material and final product, facilitating scalability and practical application in clinical settings. Finally, NÖK's focus on both hematological malignancies and solid tumors, combined with its potential for combination with antibodies, broadens its therapeutic scope and positions it to address unmet needs in diverse oncology indications, further enhancing its competitive edge.

**Company Growth Strategy**

As a clinical stage biotech company, the growth of the intrinsic value of NÖK Therapeutics is predicated on the development and commercialization of its technology and products through human clinical stages to regulatory approval. Going forward, NÖK intends to capitalize on its strengths to position the company for long term success. This will include advancing key programs such as evencaleucel and targeting high value indications. Additionally, NÖK will continue to seek and strengthen strategic collaborations and partnerships with academic institutions, biotech firms, and pharmaceutical companies. In the near term, we will enhance our GMP manufacturing capabilities to meet the production demands of future clinical trials. These advancements will come from our efforts to secure funding through non-dilutive mechanisms and through a combination of equity offerings, debt financing, or milestone-based payments from partnerships.

The Company has elected to delay complying with any new or revised financial accounting standard until the date that a company that is not an issuer (as defined under section 2(a) of the Sarbanes-Oxley Act of 2002 (15 U.S.C. 7201(a)) is required to comply with such new or revised accounting standard, if such standard also applies to companies that are not issuers.

We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year following the fifth anniversary of the completion of an Initial Public Offering (IPO), (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, as such amount is indexed for inflation every five years by the Securities and Exchange Commission to reflect the change in the Consumer Price Index for All Urban Consumers during its most recently completed fiscal year, (3) the last day of the fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such fiscal year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

For so long as we are an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not limited to:

● As a newly formed start-up company, we present only audited financial statements and related management's discussion and analysis of financial condition and results of operations in our initial registration statement;

● we avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley;

● we provide reduced disclosure about our executive compensation arrangements; and

● we do not require shareholder non-binding advisory votes on executive compensation or golden parachute arrangements.

The Company may remain an "emerging growth company" until as late as the fiscal year-end following the fifth anniversary of the completion of an IPO, though the Company may cease to be an emerging growth company earlier under certain circumstances, including if (a) the Company has more than $1.235 billion in annual revenue in any fiscal year, (b) the market value of common stock that is held by non-affiliates exceeds $700 million as of the last business day of the second quarter of its most recently completed fiscal year; or (c) we issue more than $1.0 billion of non-convertible debt over a three-year period.

In addition, Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the "Securities Act"), for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We are also a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). To the extent that we continue to qualify as a smaller reporting company after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (i) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (ii) scaled executive compensation disclosures; and (iii) the requirement to provide only two years of audited financial statements, instead of three years.

**Intellectual Property**

In May 2024, the Company entered into a patent transfer and assignment agreement with the bankruptcy estate of XNK Therapeutics AB ("XNK"), to purchase key patent families and related intellectual property related to a proprietary technology platform and autologous Natural Killer ("NK") cell therapy drug product.

**<u>NӦK Patent Families</u>**

Note regarding Patent Ownership: Cellprotect Nordic Pharmaceuticals AB sold its rights in the Patents described below to XNK. NӦK acquired all XNK's patent rights when it purchased the assets of XNK from the XNK bankruptcy estate in May of 2024.

**<u>Patent Family 1</u>**

A method of large-scale expansion and simultaneous activation of NK cells and NK-like T cells in a closed cell culture system, wherein the expanded cells exhibit increased cytotoxicity.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** | **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** | **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** | **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** | **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** | **Expansion of NK Cells**<br> **Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB** |
| **Country** | **Inventor(s)** | **Appl. No.** | **Appl. Date** | **Reg. no.** | **Exp. date** |
| Belgium | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Czech Republic | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Denmark | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Finland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| France | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Germany | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Ireland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Italy | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Luxemburg | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| the Netherlands | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Norway | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Poland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Portugal | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Spain | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Sweden | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Switzerland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| Turkey | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| UK | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Mar 2030 |
| China | Evren Alici | CN 201080021237.8 | 2010-03-25 | CN 102428173 | 25 Mar 2030 |
| Hong Kong | Evren Alici | HK 12110647.2 | 2010-03-25 | HK 1170258 | 25 Mar 2030 |
| Japan | Evren Alici | JP 2017-208238 | 2010-03-25 | JP 2018-046840 | 25 Mar 2030 |
| Republic of Korea | Evren Alici | KR 10-2011-7025234 | 2010-03-25 | 1018815200000 | 25 Mar 2030 |
| USA | Evren Alici | US 13/260,004 | 25 Mar 2010 | US 8,877,182 | 25 Mar 2030 |

---

**<u>Patent Family 2</u>**

The present invention relates to expanded NK cells. The NK cells have been expanded *ex vivo*, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** | **Title: Expanded NK Cells <br> Applicant/owner: Cellprotect Nordic Pharmaceuticals AB** |
| **Country** | **Inventor(s)** |  | **Appl. No.** | **Appl. Date** |  | **Reg. no.** | **Reg. date** | **Exp Date** |
| USA | Sirac Dilber, Evren Alici | US | 14/830,758 | 20 Aug 2015 | US | 9585914 | 7 March 2017 | 09 Nov 2027 |

---

**<u>Patent Family 3</u>**

The present invention relates generally to anti-viral agents for use in preventing herpes virus reactivation in a patient, wherein the patient has received a therapy comprising natural killer (NK) cells and/or NK-like T cells. Additionally, the invention relates to NK cells and/or NK-like T cells for use in treating a malignant disease in a patient, wherein the use comprises the step of administering an anti-viral agent to the patient with the NK cell and/or NK-like T cell therapy. The invention also relates to pharmaceutical compositions and kits.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** | **Title: Medical Uses<br> Applicant/owner: XNK Therapeutics AB** |
| **Country** | **Inventor(s)** | **Appl. No.** | **Appl. Date** | **Reg. no.** | **Reg. date** | **Renewal Date** | **Status** |
| China | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | CN 201980029357.3 | 30 April 2019 |  |  |  | Abandoned |
| EP | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | EP 3787685 | 30 April 2019 |  |  |  | Pending |
| Hong Kong | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren Ljunggren | 62021036993.5 | 30 April 2019 |  |  |  | Abandoned |
| Hong Kong | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | 62021038634.3 | 30 April 2019 |  |  |  | Pending |
| Japan | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | JP 2021-510533 | 30 April 2019 |  |  |  | Abandoned |
| Republic of Korea | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | KR 10-2020- <br> 7034431 | 30 April 2019 |  |  |  | Pending |
| US | Evren Alici, Hareth Nahi, <br> Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren | 17/04, 8702 | 30 April 2019 |  |  |  | Pending |

---

**<u>Patent Family 4</u>**

The present invention relates generally to new methods for expanding NK cells. The method comprises starting from a low number of NK cells, and recites particular perfusion conditions.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Title: Methods** | **Title: Methods** | **Title: Methods** | **Title: Methods** | **Title: Methods** | **Title: Methods** |  |
| **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** | **Applicant/owner: XNK Therapeutics AB** |
| **Country** | **Inventor(s)** | **Appl. No.** | **Appl. Date** | **Reg. no.** | **Reg. date** | **Renewal Date** | **Status** |
| EP | Jan Per-Henrik Holmqvist | EP 22809372.0 | 24 Oct 2022 | N/A | N/A | N/A | Pending |
| USA | Jan Per-Henrik Holmqvist | US 18/705176 | 24 Oct 2022 | N/A | N/A | N/A | Pending |

---

**Seasonality in Our Business**

We do not believe our business is subject to significant seasonal variation.

**Employees**

As of December 31, 2025, the Company employed five part-time employees who collectively provide operational, financial, and strategic advisory services.

**Government Regulation**

Our business is subject to a wide range of laws and regulations at the federal, state, and local levels including employment, health care and safety, privacy, data security, environmental, and other requirements. Compliance with these laws and regulations requires management by the Company, including legal assistance, use of professional employment organizations, and other resources on an ongoing basis. Changes in laws and regulations, and their variations in local jurisdictions, require monitoring and research in order to ensure compliance, and obtain the appropriate licenses, certificates, permits, and other documentation necessary to conduct business. Many of these laws and regulations are typical of most business activities, whereas we describe additional regulations at the federal level specific to our company below.

**Regulatory Process**

Our product candidate must be approved for therapeutic indications by the FDA before it may be marketed in the U.S. Our drug product candidates are regulated under the FDCA (Food Drug & Cosmetic Act) and the FDA must approve a Biologics License Application ("BLA"), which generally involves the following:

● completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice ("GLP") requirements;

● submission to the FDA of an IND which must become effective before clinical trials may begin and must be updated annually and when certain changes are made;

● approval by an institutional review board ("IRB") or independent ethics committee ("EC") at each clinical trial site before each clinical trial may be initiated;

● performance of adequate and well-controlled clinical trials in accordance with good clinical practice ("GCP") requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;

● preparation and submission to the FDA of an BLA;

● payment of user fees for FDA review of the BLA, unless waived;

● a determination by the FDA within 60 days of its receipt of an BLA to file the application for review;

● satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the product will be produced to assess compliance with Current Good Manufacturing Processes ("cGMP") to assure that the facilities, methods, and controls are adequate to ensure and preserve the drug product's identity, strength, quality and purity;

● satisfactory completion of any FDA audits of the clinical trial sites that generated the data in support of the BLA; and

● FDA review and approval of the BLA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.

**Facilities**

We do not own any plants or facilities.

**Legal Matters**

We are not currently party to any legal proceedings and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results or financial condition.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview of Operations**

NӦK was incorporated on May 22, 2024, in the state of Florida and with its primary place of business located at 2009 Mackenzie Way, Suite 100, Cranberry Twp, PA 16066. We have five employees, all of whom are part-time.

NӦK is a clinical-stage biotechnology company developing Natural Killer (NK) cell-based cancer therapies. These autologous therapies target areas within both hematological malignancies and solid tumors. NK cells play an important role in the body's protection against cancer by effectively recognizing virus-infected and tumor cells. NK cells kill both cell types and also interact with other cells making them vital in innate immune defense.

The NӦK proprietary technology platform and autologous NK cell therapy drug product is designed to target cancer, especially in situations where autologous therapies have a clear benefit over allogeneic therapies. Platform enabling selective expansion and activation of NK cells from cancer patient's peripheral blood produces NK cells with increased tumor killing ability. NӦK's strategy is repeated dosing of long lived autologous re-activated NK cells and achieve tumor targeting by combining with established antibody-dependent cell-mediated cytotoxicity (ADCC) competent monoclonal antibodies (mAbs), exerting their anti-tumor effect by binding to the tumor and recruiting NK cells.

NӦK's hematological malignancy clinical stage pipeline candidate, evencaleucel, has completed first in human Phase I for safety and tolerability in multiple myeloma patients. Treatment with escalating doses of ex vivo activated and expanded NK cells was well tolerated without any severe adverse events. The second hematological candidate, indicated for acute myeloid leukemia (AML), NOK02, along with our two candidates, NOK03 and NOK4 for solid tumors, are in preclinical stages. The rights to develop evancaleucel were acquired during the purchase by NӦK of all assets of XNK from its bankruptcy estate in May 2024.

**Recent Developments**

Recent developments have focused on securing EU manufacturing capacity, culminating in the selection of a CDMO with the infrastructure, quality systems, and technical capabilities required to support upcoming human clinical trials.

**Results of Operations** 

**<u>Gross revenue</u>**: The Company had no revenue during the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024.

**<u>Research and development expenses</u>**: The Company incurred $163,164 and $223,314 in research and development expenses during the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, respectively. These expenses were primarily associated with the purchase of key patent families and related intellectual property related to the proprietary technology platform and autologous NK cell therapy drug product, patent expenses, and other preparatory activities necessary to support the next phase of our trial. The decrease in research and development expenses is primarily driven by the purchase of key patent families and related intellectual property in 2024.

**<u>Other operating expenses</u>**: The Company incurred $1,827,336 and $79,782 in other operating expenses, including salaries and wages, professional services, and general and administrative expenses during the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, respectively. The significant increase in 2025 is primarily a result of salaries and wages and increased professional services expenses.

**<u>Other expense, net:</u>** The company had $1,011,410 and $71,269 in net other expenses for the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, respectively. This includes interest expense, loss on extinguishment of debt, change in fair value of liabilities, and other income (expense). The increase in other expense is primarily due to the loss recognized in connection with the conversion of the $250,000 promissory note in May 2025. Please see Note 3 – Debt.

**<u>Net loss:</u>** Net loss for the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, was $3,001,910 and $374,365, respectively. The change in net loss is primarily driven by the increase in professional services expenses and loss recognized in connection with the conversion of the $250,000 promissory note.

**Liquidity and Capital Resources** 

As of December 31, 2025, we had cash of $206,042. During the year ended December 31, 2025, we used approximately $1,107,996 in cash for operating activities and were provided $893,600 through financing activities.

In fiscal year 2024, the Company entered into unsecured note agreements with certain shareholders in the aggregate principal amount of $172,500. These notes bear interest at 6% per annum and with a maturity date of May 28, May 31, and June 28, 2026. Upon the occurrence and during the continuance of any default by the Company under these notes, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable.

In fiscal year 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $100,000. The note bears interest of at 6% per annum and a maturity date on April 8, 2025. Upon the occurrence and during the continuance of any default by the Company under the note, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As additional consideration for the note, the Company agreed to issue 100,000 shares of our common stock to the note holder.

In fiscal year 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $250,000. The note bears interest of at 6% per annum and a maturity date on May 11, 2025. Upon the occurrence and during the continuance of any default by the Company under the note, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As additional consideration for the note, the Company agreed to issue 250,000 shares of our common stock to the note holder. In May, 2025, the principal of this note was converted into 1,000,000 shares of common stock and accrued interest in the amount of $7,438 was paid in cash.

In fiscal year 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $250,000. These note bears interest of $50,000 and matures on March 16, 2026. Interest and principal on the note is paid in an amount equal to fifty (50) percent of net proceeds, less expenses, from the sale of the Company's Regulation A filing. All unpaid principal and interest is paid at maturity. Upon the occurrence and during the continuance of any default by the Company under the note, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As additional consideration for the note, the Company agreed to issue 250,000 shares of our common stock to the note holder. The note had an outstanding principal balance of $250,000 as of March 31, 2026 and accrued interest of $50,000. The note is currently in default.

The capital raised through this offering, combined with our existing cash on hand, may be sufficient to meet all financial needs and obligations for the next twelve months. However, our liquidity needs are affected by changes in business operations, including investments in product development.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate the continuation of the Company as a going concern, which is dependent upon the Company's ability to obtain sufficient financing or establish itself as a profitable business. As of December 31, 2025, the Company had an accumulated deficit of $3,376,275 and net loss of $3,001,910 and had not yet commenced revenue generating activities. These conditions raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the financial statements are issued.

The Company's continuation as a going concern is dependent upon its ability to obtain additional financing, generate revenues, and ultimately achieve profitable operations. We may seek additional capital resources through public or private debt or equity offerings to support future growth opportunities or other corporate purposes. However, there can be no assurance that additional financing will be available on favorable terms, or at all.

Our liquidity may be impacted by a number of risks and uncertainties, including:

● Economic Conditions: A downturn in the economy could negatively affect our ability to raise capital.

● Credit Market Volatility: If the credit markets remain restrictive, our ability to obtain financing on favorable terms may be limited.

● Operational Risks: Any disruptions in our operations, including supply chain issues or regulatory changes, could impact our ability to raise capital.

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this document, we believe that the accounting policies discussed above are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management's estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

**<u>Cash Flows</u>**

 ****

***Cash Flow used in Operating Activities***

For the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, the Company used $1,107,996 and $348,462 in operating activities, respectively. The cash used in operations was primarily attributable to research and development expenses, general and administrative costs, and personnel-related expenses. As a pre-revenue development-stage company, we expect to continue incurring negative cash flows from operations in the near term as we advance our clinical and regulatory program.

 ****

 ****

***Cash Flows from Financing Activities***

The Company generated $893,600 and $768,900 in net cash from financing activities for the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024, respectively. This amount primarily reflects proceeds from the issuance of common stock, which were used to fund initial operating and development activities. The Company made debt repayments of $150,000 during the period.

**Material Cash Commitments.** The Company's material future cash commitments, to be paid from cash flows from operations, are to repay its current debt obligations. The Company does not have any material commitments for capital expenditures. The following table shows the material future commitments for the years ending December 31:

---

| | |
|:---|:---|
| 2026 | $291758 |
| Total | $291758 |

---

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.

**Item 3. Directors and Officers**

The following table sets forth the name, age, and position of our executive officers and directors. Executive officers are elected annually by our Board of Directors. Each executive officer holds his office until he resigns, is removed by the Board, or his successor is elected and qualified. All of the current directors are in the first year of a three year term. Each director holds his office until his successor is elected and qualified or his earlier resignation or removal.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Robert Lewis | 55 | President, CEO and Director |
| Brian Cogley | 40 | Chief Financial Officer and Director |
| Tamara Jovonovich | 59 | Chief Operating Officer |
| Bruce Cassidy | 75 | Director |
| Martin Lewis | 65 | Director |

---

**Robert Lewis, (President, CEO and Director).** Mr. Lewis has served as President, Chief Executive Officer and Director of NӦK Therapeutics, Inc. since June of 2024, working approximately twenty hours per week since inception. Rob currently serves in a part-time capacity as Chief Operating Officer and member of the board of Jabez Biosciences, Inc. as well as a member of the board of RAAx, Inc. Rob spent the last 30 years working in the pharmaceutical industry, beginning at TEVA Pharmaceuticals and continuing with other multiple global and mid-tier pharmaceutical corporations such as Sigma and Cypress Pharmaceuticals. Rob has held leadership positions overseeing the departments of Scientific Affairs, Medical Affairs, Regulatory Affairs, Clinical Affairs, and International and Domestic Business Development. Additionally, Rob has 30 NDA and ANDA FDA drug approvals and multiple launches under his supervision. Since 2012, Rob has been self employed as a health care consultant, co-founded and taken multiple ownership stakes in other biotech, pharmaceutical, and medical device companies and serves on the board of directors for each company. Rob earned his B.S. in Chemistry & Biology from Columbia College.

**Brian Cogley, (Chief Financial Officer, Director).** Mr. Cogley joined NӦK Therapeutics, Inc. in June of 2024 and joined the Board of Directors in August of 2024. Mr. Cogley is serving as the Company's Chief Financial Officer in a part-time capacity, working approximately ten hours per week since inception, until a time when the Company determines a full-time position is necessary. Mr. Cogley is the full time CFO for Z Squared Inc. (Nasdaq:ZSQR) and that is his full time and primary position. In addition, Mr. Cogley serves in a part-time capacity with Jabez Biosciences, Inc. and a member of its Board of Directors. Mr. Cogley has over 16 years of accounting and finance experience, having previously held positions of increasing authority at two "Big 4" public accounting firms and served on the management teams of multiple companies in diverse industries. An accountant by training, Mr. Cogley arrives at NÖK with a career in corporate finance and accounting during which he advised and led the financial operations for companies spanning multiple industries including life sciences, pharmaceuticals, financial services, and manufacturing. In May 2023, Mr. Cogley joined the executive team of Coeptis Therapeutics Holdings, Inc. as the Chief Financial Officer. From February 2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles, segment reporting and carve-out engagements. From 2017-2022 Mr. Cogley held the position of Vice President of Finance & Accounting at NexTier Bank where he was a member of the Company's senior management team and led its accounting and finance operations, including the general ledger, financial planning and analysis, internal and external financial reporting, and human resources. From 2015-2017 Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. From 2012-2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building its Sarbanes-Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on various process improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Business Administration with a concentration in finance from Duquesne University.

**Tamara Jovonovich, (Chief Operating Officer).** Dr. Jovonovich co-founded Jabez Biosciences, Inc. in 2023, marking her 20th year in the pharmaceutical industry, working approximately thirty hours per week since inception. In her tenure, Tamara has contributed to 15+ FDA drug approvals. Tamara lectured at San Jose University in 2004 before joining Alexza Pharmaceuticals (Ferrer) from 2004-2005. From 2005-2009, Tamara was a Principal Investigator at Fleming Pharmaceuticals (acquired by Long Pharmaceutical), developing various drug products for regulatory filings and approvals, both abbreviated and new. From 2009 to 2017, Tamara was a Director of Drug Development for Cypress Pharmaceuticals (acquired by Pernix Therapeutics). Tamara founded a consulting business in 2018-2024 where as President she helped several companies in the areas of development, manufacturing, quality and regulatory to develop, approve and maintain prescription products. Tamara is a co-founder and equity partner in other start-up biotech companies. Tamara attended the University of Central Florida where she earned a BS in Chemistry in 1996 and a BS in Fine Arts in 1996; the University of Washington where she earned a PhD in Biophysical Chemistry in 2000; and Stanford University where she earned a Fellowship in Chemistry from 2001-2004.

**Bruce A. Cassidy, (Director)**. Mr. Cassidy joined our Board of Directors in August of 2024. In addition to his role on our Board of Directors, Mr. Cassidy currently serves on the boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021), as a member of the board of Oragenics, Inc. (October 2023) and a member of the board of Jabez Biosciences, Inc. (August 2024). He was also the founding investor and served on the board of directors of Ohio Legacy Corp. Previously, Mr. Cassidy was the founder and CEO of Excel Mining Systems from 1991 until its sale in 2007 to Orica Mining Services, and from 2008 to 2009, he served as the President and CEO of one of its subsidiaries, Minora North & South Americas. He is currently the President of The Concession Golf Club in Sarasota, Florida. Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

**Martin Lewis, (Director).** Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis is also a member of the board of directors of Jabez Biosciences, Inc. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Prior to joining the firm, he developed his accounting skills working for Mesa Petroleum Company working on joint interest billings and offshore operations. Mr. Lewis received his bachelor's degree in accounting with emphasis in Petroleum Accounting, from Texas Tech University in 1982. He also served as a former adjunct professor at Wayland Baptist University. Over the years, Mr. Lewis has been involved in management consulting for a wide variety of West Texas clients. He has developed a recognized specialty in the agricultural, financial institution & healthcare industries, including single and multi-physician medical practices. Mr. Lewis has contributed to the growth of the firm and is deeply committed to client service and to the personal and professional growth of his associates. He was elevated to stockholder in 1991. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

**Family Relationships**

No director, executive officer, or individual nominated or selected to become a director or executive officer has any family relationship, whether by blood, marriage, or adoption, that is closer than first cousin.

**Involvement in Certain Legal Proceedings**

The Company's directors and officers have not been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors, nor have been a party to any judicial or administrative proceeding during the past ten years that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws, except for matters that were dismissed without sanction or settlement.

Except as set forth in our discussion below in "Certain Relationships and Related Transactions," our directors and officers have not been involved in any transactions with us or any of our affiliates or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.

**Executive Compensation**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year<br> Ended** | **Salary<sup>2</sup><br> ($)** | **Bonus<br> ($)** | **Option<br> Awards<br> ($)** | **Nonequity<br> Incentive Plan<br> Compensation<br> ($)** | **Non-<br> Qualified<br> Deferred<br> Compensation<br> Earnings <br> ($)** | **All Other<br> Compensation<br> ($)** | **Total<br> ($)** |
| Robert Lewis, | 2025 | 125000 |  |  |  |  |  | 125000 |
| &nbsp;&nbsp;&nbsp;President, CEO | 2024 | 14423 |  |  |  |  |  | 14423 |
| Brian Cogley, | 2025 | 75000 |  |  |  |  |  | 75000 |
| &nbsp;&nbsp;&nbsp;CFO | 2024 | 8654 |  |  |  |  |  | 8654 |
| Tamara Jovonovich, | 2025 | 115000 |  |  |  |  |  | 115000 |
| &nbsp;&nbsp;&nbsp;COO | 2024 | 13269 |  |  |  |  |  | 13269 |

---

**<sup>1</sup>** Directors, Martin Lewis and Bruce Cassidy, receive no compensation from the Company for their service at this time.

**<sup>2</sup>** The Company was incorporated on May 22, 2024. The Company began paying employees pro-rated annual starting salaries on November 29, 2024. The annual starting salaries as follows: Robert Lewis, President, CEO, $125,000; Brian Cogley, CFO (Interim and Part-Time), $75,000; Tamara Jovonovich, COO, $115,000. The Company may choose to increase salaries in 2026.

**Emerging Growth Company Status**

As an emerging growth company, we are currently exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

**Employment Agreements**

We have not entered into employment agreements with any of our employees, officers and directors.

**Item 4. Security Ownership of Management and Certain Securityholders**

**Principal Stockholders\***

The following table sets forth information as to the shares of common stock beneficially owned as of April 27, 2026 by (i) each person known to us to be the beneficial owner of more than 10% of our common stock; and (ii) all of our Directors and Executive Officers as a group. Unless otherwise indicated in the footnotes following the table, the persons as to whom the information is given had sole voting and investment power over the Shares of common stock shown as beneficially owned by them. Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act, which generally means that any shares of common stock subject to options currently exercisable or exercisable within 60 days of the date hereof are considered to be beneficially owned, including for the purpose of computing the percentage ownership of the person holding such options, but are not considered outstanding when computing the percentage ownership of each other person. We currently have no options outstanding.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Address** | **Shares** | **%<br> Ownership<sup>(1)</sup>** |
| Robert Lewis | 2009 Mackenzie Way, Suite 100, <br> Cranberry Twp, PA 16066 | 5800000 | 12.35% |
| Brian Cogley | 2009 Mackenzie Way, Suite 100, <br> Cranberry Twp, PA 16066 | 447200 | 0.95% |
| Tamara Jovonovich | 2009 Mackenzie Way, Suite 100, <br> Cranberry Twp, PA 16066 | 430000 | 0.92% |
| Eagle Investment Group (Bruce Cassidy, Control Person) | 1258 North Palm Ave., Sarasota, FL 34109 | 4350000 | 9.26% |
| Marlew, LTD. (Martin Lewis, Control Person) | 2308 W 5<sup>th</sup> Street, Plainview, TX 79072 | 8905121 | 18.96% |
| MedTek, LLC (Martin Lewis, Control Person) | 2308 W 5<sup>th</sup> Street, Plainview, TX 79072 | 1632500 | 3.48% |
| Total Officers and Directors As a Group |  | 21564821 | 45.91% |
| NCF Charitable Assets Trust, NCF Giving INC, TTEE (Bradley Orr, Control Person) | 5114 Balcones Woods DR STE 307 Austin, TX 78759 | 6020750 | 12.82% |

---

<sup>(1)</sup> Based on 46,968,550 shares issued and outstanding as of April 27, 2026

**Item 5. Interest of Management and Others in Certain Transactions**

**CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

**Related Party Transactions**

On September 24, 2024, the Company entered into a stock purchase agreement with Eagle Investment Group, LLC for 4,350,000 shares of common stock for total consideration of $250,000 payable in two payments with the first payment of $100,000 payable on or before September 27, 2024 and the second payment of $150,000 payable on or before November 15, 2024. The Company had a subscription receivable of $150,000 as of December 31, 2024. The transaction was completed in January 2025, at which time the Company issued the corresponding shares. Bruce Cassidy, Director, is a Control Person of Eagle Investment Group, LLC.

In and between April 2025 and October 2025, the Company entered into stock subscription agreements with MedTek, LLC for 632,500 shares of common stock at $1.00 per share in private transactions exempt from registration under Regulation D, Rule 506(b) of the Securities Act. Martin Lewis, Director, is a control person of MedTek, LLC.

In November 2025, the Company entered into stock subscription agreements with MedTek, LLC for 1,000,000 shares of common stock at $0.25 per share in a private transaction exempt from registration under Regulation D, Rule 506(b) of the Securities Act. Martin Lewis, Director, is a control person of MedTek, LLC.

**Shareholder Loans**

 

In May 2024, the Company entered into an unsecured note agreement with GoLabs Research and Development LLC in the principal amount of $150,000 together with interest of 6%, with a maturity date of May 28, 2026. Martin Lewis, Director, is a Control Person of GoLabs Research and Development LLC. As of December 31, 2024, the remaining principal balance on the unsecured note is $50,000 and accrued interest on the note was $4,027. In January 2025, the Company paid the outstanding $50,000 principal balance of the unsecured note agreement including accrued interest of $4,126.

*Indemnification of Officers and Directors*

Our Bylaws include provisions that provide for indemnification, expense advancement and reimbursement for our directors and officers, to the maximum extent allowable under Florida law. We plan to enter into customary indemnification agreements with our officers or directors. We currently maintain directors' and officers' insurance covering certain liabilities that may be incurred by directors and officers in the performance of their duties.

**Transfer Agent and Registrar**

The transfer agent and registrar for our common stock is ClearTrust, LLC.

**Stock Market Listing**

Our shares of common stock are not listed or authorized for listing on any stock exchange.

**Limitations on Liability and Indemnification of Officers and Directors**

Florida law authorizes corporations to limit or eliminate (with a few exceptions) the personal liability of directors to corporations and their shareholders for monetary damages for breaches of directors' fiduciary duties as directors. Our Articles of Incorporation and Bylaws include provisions that eliminate, to the maximum extent allowable under Florida law, the personal liability of directors or officers for monetary damages for actions taken as a director or officer, as the case may be. Our Articles of Incorporation and Bylaws also provide that we must indemnify and advance reasonable expenses to our directors and officers to the fullest extent permitted by Florida law. We are also expressly authorized to carry directors' and officers' insurance for our directors, officers, employees and agents for some liabilities. We currently maintain directors' and officers' insurance covering certain liabilities that may be incurred by directors and officers in the performance of their duties.

The limitation of liability and indemnification provisions in our Articles of Incorporation and Bylaws may discourage shareholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. In addition, your investment may be adversely affected to the extent that, in a class action or direct suit, we pay the costs of settlement and damage awards against directors and officers pursuant to the indemnification provisions in our Articles of Incorporation and Bylaws.

There is currently no pending litigation or proceeding involving any of the directors, officers or employees for which indemnification is sought.

In so far as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Item 6. Other Information**

**Unregistered Sales of Securities**

The following is a summary of transactions by the Company from inception to December 31, 2025 involving sales of our securities that were not registered under the Securities Act.

In May and June 2024, the Company sold unsecured notes in the aggregate principal amount of $172,500. The notes were sold by us for cash, at par in private transactions exempt from registration under Section 4(a)(2) of the Securities Act.

In June 2024, the Company issued 18,800,000 shares of common stock to the founders, officers, directors for nominal cash and/or services in transactions exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In June 2024, the Company sold 10,959,000 shares of common stock for nominal cash in transactions exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between August 2024 and September 2024, the Company sold 650,000 shares of common stock for nominal cash in transactions exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

From August to October 2024, we sold 16,500 shares of common stock at $1.00 per share in a private transaction exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In September 2024, we sold 4,350,000 shares of common stock for $250,000 in a transaction exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between October 2024 and December 2024, we sold unsecured notes in an aggregate principal amount of $600,000. The notes were sold by us for cash, at par. As partial consideration for the notes, we issued 600,000 shares of common stock. We did not receive any cash consideration for these shares. These transactions were private transactions exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between January 2025 and September 2025, we issued 880,000 shares of common stock in exchange for services in transactions exempt from registration pursuant to Rule 701 of the Securities Act.

In March 2025, we issued 5,700,000 shares of common stock to an officer and director in a private transaction exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between May 2025 and November 2025, we sold 2,000,000 shares of common stock at $0.25 per share in private transactions exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between April 2025 and October 2025, we sold 632,500 shares of common stock at $1.00 per share in a private transaction exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between July 2025 and September 2025, we sold 4,900 shares of common stock at $2.00 per share under Regulation A.

In August 2025, we sold 1,000,000 shares of common stock for $500 in a private transaction exempt from registration pursuant to Rule 506(b) Regulation D of the Securities Act.

In and between May 2025 and November 2025, we sold 2,000,000 shares of common stock at $0.25 per share in private transactions exempt from registration pursuant to 506(b) Regulation D of the Securities Act.

**EXPERTS**

The financial statements of NÖK Therapeutics, Inc. as of December 31, 2025 and 2024 have been so included in reliance on the report of Astra Audit & Advisory, LLC of Tampa, Florida a registered PCAOB CPA firm, appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.

**Item 7. Financial Statements**

**NÖK THERAPEUTICS, INC.**

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

DECEMBER 31, 2025 AND 2024

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **[Report of Independent Registered Public Accounting Firm](#f_001)** | **F-2** |
| **[Balance Sheets, as of December 31, 2025 and 2024](#f_002)** | **F-3** |
| **[Statements of Operations, for the Year Ended December 31, 2025 and for the Period from Inception (May 22, 2024) to December 31, 2024](#f_003)** | **F-4** |
| **[Statements of Stockholders' (Deficit) Equity, for the Year Ended December 31, 2025 and for the Period from Inception (May 22, 2024) to December 31, 2024](#f_004)** | **F-5** |
| **[Statements of Cash Flows, for the Year Ended December 31, 2025 and for the Period from Inception (May 22, 2024) to December 31, 2024](#f_005)** | **F-6** |
| **[Notes to Financial Statements](#f_006)** | **F-7** |

---

![](ea028757101_img1.jpg)

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and<br> Stockholders of NöK Therapeutics, Inc.

**Opinion on the Financial Statements**

We have audited the accompanying balance sheets of NöK Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, and the related statements of operations, stockholders' (deficit) equity and cash flows for the year ending December 31, 2025 and the period from inception (May 22, 2024) to December 31, 2024, and the related notes and schedules (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the year ending December 31, 2025 and the period from inception (May 22, 2024) to December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

**Substantial Doubt about the Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has no current operations and negative operating cash flows. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

![](ea028757101_img2.jpg)

We have served as the Company's auditor since 2024.

Tampa, Florida

April 30, 2026

**3702 W Spruce St #1430 ● Tampa, Florida 33607 ● +1.813.441.9707**

**NÖK THERAPEUTICS, INC.**

**BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **December 31, 2025** | **December 31, 2024** |
| **ASSETS** | | |
| **CURRENT ASSETS** | | |
| &nbsp;&nbsp;&nbsp;Cash | $206042 | $420438 |
| &nbsp;&nbsp;&nbsp;Prepaid assets | 1080 | 1077 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | 66812 | 66812 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT ASSETS | 273934 | 488327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL ASSETS | $273934 | $488327 |
| **LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY** |  |  |
| **CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable, current, net of debt discount of $20,637 and $117,368, respectively | $229363 | $232632 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 23515 | 12573 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable, current | 41758 | 3436 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 12912 | 10384 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT LIABILITIES | 307548 | 259025 |
| **LONG TERM LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Note payable, long term, net of debt discount of $0 and $121,071, respectively |  | 178929 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable, long term | - | 5677 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LONG TERM LIABILITIES | - | 184606 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LIABILITIES | 307548 | 443631 |
| **COMMITMENTS AND CONTINGENCIES (NOTE 5)** |  |  |
| **STOCKHOLDERS' (DEFICIT) EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.00 par value, 10,000,000 shares authorized, 0 issued and outstanding at December 31, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.00 par value, 100,000,000 shares authorized, 46,968,550 and 35,375,500 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3342661 | 569061 |
| &nbsp;&nbsp;&nbsp;Subscription receivable |  | (150000) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (3376275) | (374365) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | (33614) | 44696 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | $273934 | $488327 |

---

*The accompanying notes are an integral part of this financial statement.*

**NÖK THERAPEUTICS, INC.**

**STATEMENTS OF OPERATIONS**

---

| | | |
|:---|:---|:---|
|  | **For the Year Ended <br> December 31, 2025** | **For the Period from Inception (May 22, 2024) to<br> December 31, 2024** |
| **SALES** | | |
| &nbsp;&nbsp;&nbsp;Sales | $- | $- |
| &nbsp;&nbsp;&nbsp;Cost of goods sold | - | - |
| &nbsp;&nbsp;&nbsp;Gross profit |  |  |
| **COST OF OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Research and development expense | 163164 | 223314 |
| &nbsp;&nbsp;&nbsp;Salaries and wages expense | 475709 | 64036 |
| &nbsp;&nbsp;&nbsp;Professional services expense | 1307775 | 14501 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 43852 | 1245 |
| &nbsp;&nbsp;&nbsp;Total cost of operations | 1990500 | 303096 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOSS FROM OPERATIONS | (1990500) | (303096) |
| **OTHER (EXPENSE) INCOME** |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (265004) | (71269) |
| &nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | (841696) |  |
| &nbsp;&nbsp;&nbsp;Change in fair value of put liability | 91696 |  |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 3594 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL OTHER (EXPENSE), NET | (1011410) | (71269) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOSS BEFORE INCOME TAXES | (3001910) | (374365) |
| **PROVISION FOR INCOME TAXES** | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NET LOSS | $(3001910) | $(374365) |
| **LOSS PER SHARE** |  |  |
| &nbsp;&nbsp;&nbsp;Loss per share, basic and fully diluted | $(0.07) | $(0.01) |
| &nbsp;&nbsp;&nbsp;Weighted average number of common shares outstanding | 42828600 | 28303283 |

---

*The accompanying notes are an integral part of this financial statement.*

**NÖK THERAPEUTICS, INC.**

**STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY**

**For the Year Ended December 31, 2025 and for the Period from Inception (May 22, 2024) to December 31, 2024**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **PREFERRED STOCK** | **PREFERRED STOCK** | **COMMON STOCK** | **COMMON STOCK** | | | | |
|  | **SHARES** | **AMOUNT** | **SHARES** | **AMOUNT** | **SHARES**<br>**SUBSCRIBED** | **SUBSCRIPTION**<br>**RECEIVABLE** | **ACCUMULATED**<br>**DEFICIT** | **TOTAL**<br>**EQUITY** |
| BALANCE AT MAY 22, 2024 |  | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |  | $- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $- | $- | $- |
| &nbsp;&nbsp;&nbsp;Shares issued for cash |  |  | 34775500 | 268900 |  | (150000) |  | 118900 |
| &nbsp;&nbsp;&nbsp;Shares issued with notes payable |  |  | 600000 | 300161 |  |  |  | 300161 |
| &nbsp;&nbsp;&nbsp;Net loss |  | - | - | - | - | - | (374365) | (374365) |
| BALANCE AT DECEMBER 31, 2024 |  | - | 35375500 | $569061 | $- | $(150000) | $(374365) | $44696 |
| &nbsp;&nbsp;&nbsp;Shares issued for cash |  |  | 9713050 | 893600 |  | 150000 |  | 1043600 |
| &nbsp;&nbsp;&nbsp;Shares issued for services |  |  | 880000 | 880000 |  |  |  | 880000 |
| &nbsp;&nbsp;&nbsp;Shares issued for conversion of debt |  |  | 1000000 | 1000000 |  |  |  | 1000000 |
| &nbsp;&nbsp;&nbsp;Net loss |  | - | - | - | - | - | (3001910) | (3001910) |
| BALANCE AT DECEMBER 31, 2025 |  | $- | $46968550 | $3342661 | $- | $- | $(3376275) | $(33614) |

---

*The accompanying notes are an integral part of this financial statement.*

**NÖK THERAPEUTICS, INC.**

**STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **For the Year Ended December 31, 2025** | **For the Period from Inception (May 22, 2024) to<br> December 31, 2024** |
| **OPERATING ACTIVITIES** | | |
| &nbsp;&nbsp;&nbsp;Net loss | $(3001910) | $(374365) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on writedown of liability | (91696) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount | 217802 | 61723 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares issued for non-employee services | 880000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 841696 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Increase) decrease in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid assets | (3) | (1076) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred offering costs |  | (66812) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 10942 | 12573 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest payable | 32645 | 9111 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 2528 | 10384 |
| NET CASH USED IN OPERATING ACTIVITIES | (1107996) | (348462) |
| **INVESTING ACTIVITIES** |  |  |
| NET CASH USED IN INVESTING ACTIVITIES | - | - |
| **FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from notes payable |  | 772500 |
| &nbsp;&nbsp;&nbsp;Repayment of notes payable | (150000) | (122500) |
| &nbsp;&nbsp;&nbsp;Shares issued for cash | 1043600 | 118900 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 893600 | 768900 |
| NET INCREASE (DECREASE) IN CASH | (214396) | 420438 |
| CASH AT BEGINNING OF PERIOD | 420438 | - |
| CASH AT END OF PERIOD | $206042 | $420438 |
| **SUPPLEMENTAL CASH FLOW DISCLOSURES** |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid | $14556 | $435 |
| &nbsp;&nbsp;&nbsp;Taxes paid | $- | $- |
| **SUPPLEMENTAL NON-CASH DISCLOSURES** |  |  |
| &nbsp;&nbsp;&nbsp;Shares issued in exchange for subscriptions receivable | $- | $150000 |
| &nbsp;&nbsp;&nbsp;Shares issued in exchange for notes payable | $- | $300161 |
| &nbsp;&nbsp;&nbsp;Shares issued for conversion of debt | $1000000 | $- |

---

*The accompanying notes are an integral part of this financial statement.*

**NÖK THERAPEUTICS, INC.**

**NOTES TO FINANCIAL STATEMENTS**

**December 31, 2025 and 2024**

**NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION**

**Nature of Business**

NÖK Therapeutics, Inc. ("NÖK", the "Company") was incorporated in the state of Florida on May 22, 2024. The Company is a biotechnology company developing natural killer ("NK") cell-based therapies. The current business model is designed around furthering the development of its current product portfolio in new and exciting therapeutic areas such as oncology.

**Basis of Presentation** – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). In the opinion of management, the accompanying financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, and cash flows.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Cash** – For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit of $250,000. The uninsured balance was $0 and $170,438 at December 31, 2025 and December 31, 2024, respectively. The Company regularly monitors the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.

**Income Taxes –** The Company accounts for income taxes in accordance with Accounting Standards Codification ("ASC") 740, *Income Taxes*. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses that are available to offset future federal income taxes.

ASC 740 clarifies the accounting and reporting for uncertainties in income tax law within subtopic ASC 740-10-25-5. The guidance prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. Management believes that there is no liability related to uncertain tax positions as of December 31, 2025 and December 31, 2024.

**Use of Estimates –** The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Adoption of New Accounting Pronouncements –** During the year ended December 31, 2025 and the period from inception (May 22, 2024) to December 31, 2024, there were new accounting pronouncements issued by the Financial Accounting Standards Board ("FASB"). Each of these pronouncements, as applicable, including Accounting Standards Update ("ASU") 2023-07, has been or will be adopted by the Company. Please see Note 9, Segment Reporting. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company's financial statements.

**Going Concern Risk –** The accompanying financial statements have been prepared in conformity with GAAP, which contemplate the continuation of the Company as a going concern, which is dependent upon the Company's ability to obtain sufficient financing or establish itself as a profitable business. As of December 31, 2025, the Company had an accumulated deficit of $3,376,275. For the year ended December 31, 2025, the Company had a net loss of $3,001,910 and had not yet commenced revenue generating activities. These conditions raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the financial statements are issued.

The Company's continuation as a going concern is dependent upon its ability to obtain additional financing, generate revenues, and ultimately achieve profitable operations. Management is actively pursuing funding opportunities and has demonstrated the ability to raise capital. However, there can be no assurance that management will be successful in obtaining additional funding or in attaining profitable operations.

**Fair Value of Financial Instruments** – The Company calculates the fair value of its assets and liabilities which qualify as financial instruments and includes this additional information in the notes to financial statements when the fair value is different than the carrying value of those financial instruments. The methods and assumptions applied in determining the fair value of each class of financial assets and financial liabilities of the Company are disclosed in the respective accounting policies. The estimated fair value of cash and subscriptions receivable approximate their carrying amounts due to the short-term nature of these instruments. For debt instruments issued at a discount, the carrying amount is initially recorded net of the unamortized discount, which is amortized to interest expense over the term of the debt using the effective interest method. When measuring fair value, the Company considers the impact of the discount, along with other relevant inputs such as market interest rates, credit spreads, and the terms of the instrument.

**Earnings Per Share** – Basic earnings per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect on the loss per share, only the basic earnings (loss) per share is reported in the accompanying financial statements. The Company does not have other potentially issuable shares of stock.

**Research and Development –** Research and development costs are expensed when incurred. During the year ended December 31, 2025 and the period from inception (May 22, 2024) to December 31, 2024, research and development expenses totaled $163,164 and $223,314, respectively.

**Segment Reporting** – Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The Company is operating in one segment, Biotechnology. This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline.

**Deferred Offering Costs** – Deferred offering costs, consisting primarily of legal, accounting, and other fees directly related to the Company's planned equity or debt offerings, are capitalized on the balance sheet. These costs are deferred until the completion of the related offering, at which time they are reclassified to equity (as a reduction of additional paid-in capital) or to debt (as a reduction of the carrying amount of the debt), depending on the nature of the offering. If the offering is abandoned, such costs are expensed immediately in the period in which the offering is terminated. At December 31, 2025 and December 31, 2024, the Company recorded $66,812 of deferred offering costs.

**NOTE 3 – DEBT**

In May 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $150,000 together with interest of 6%, with a maturity date of May 28, 2026. On October 11, 2024, the Company made a $100,000 payment toward the principal, leaving a remaining balance of $50,000. As of December 31, 2024, the accrued interest on this note was $4,027, classified as long-term. The note was paid in full on January 13, 2025, including accrued interest of $4,126. Additional information on this related party note is discussed in Note 8, Related Party Transactions.

In May 2024, the Company entered into an unsecured note agreement with a third party in the principal amount of $12,500 together with interest of 6%, with a maturity date of May 31, 2026. This note was paid in full on October 7, 2024, including accrued interest of $267.

In June 2024, the Company entered into an unsecured note agreement with a third party in the principal amount of $10,000 together with interest of 6%, with a maturity date of June 28, 2026. This note was paid in full on October 7, 2024, including accrued interest of $168.

In October 2024, the Company entered into a financing agreement with a third party under which it issued a promissory note with a principal amount of $100,000 together with interest of 6%, payable at maturity on April 8, 2025. As part of the financing agreement, the Company also issued 100,000 shares of its common stock to the lender. The relative fair value of the common stock was determined to be $49,989, which was recorded as a debt discount and will be amortized over the term of the note using the effective interest rate method.

As of December 31, 2024, the unamortized debt discount was $26,917, and the net carrying amount of the debt was $73,083. Amortization expense related to the debt discount for the period from inception (May 22, 2024) to December 31, 2024 was $23,072 and is included in interest expense in the accompanying statements of operations. The note had an outstanding principal balance of $100,000 as of December 31, 2024 and accrued interest of $1,382, classified as current. The note was paid in full on April 9, 2025, including accrued interest of $2,992. Amortization expense related to the debt discount for the year ended December 31, 2025 was $26,917 and is included in interest expense in the accompanying statements of operations.

In November 2024, the Company entered into a financing agreement with a third party under which it issued a promissory note with a principal amount of $250,000 together with interest of 6%, payable at maturity on May 11, 2025. As part of the financing agreement, the Company also issued 250,000 shares of its common stock to the lender. The relative fair value of the common stock was determined to be $124,973, which was recorded as a debt discount and will be amortized over the term of the note using the effective interest rate method.

As of December 31, 2024, the unamortized debt discount was $90,450, and the net carrying amount of the debt was $159,550. Amortization expense related to the debt discount for the period from inception (May 22, 2024) to December 31, 2024 was $34,523 and is included in interest expense in the accompanying statements of operations. The note had an outstanding principal balance of $250,000 as of December 31, 2024 and accrued interest of $2,055. On May 29, 2025, the principal amount of $250,000 was converted to 1,000,000 shares of common stock, which was valued at $1,000,000. and accrued interest payable in the amount of $7,438 was paid in cash. The note holder was issued a put option, which entitled him to require the Company to repurchase 250,000 shares of common stock for a price of $300,000 on the six month anniversary of the conversion, November 29, 2025. The Company recognized a loss on extinguishment of debt of $841,696 in relation to the shares and put option issued. The note holder allowed the put option to expire, and the Company recognized $91,696 of income related to the change in the fair value of the put liability. Amortization expense related to the debt discount for the year ended December 31, 2025 was $90,450 and is included in interest expense in the accompanying statements of operations.

In December 2024, the Company entered into a financing agreement with a third party under which it issued a promissory note with a principal amount of $250,000 together with interest of 16%, payable at maturity on March 16, 2026. As part of the financing agreement, the Company also issued 250,000 shares of its common stock to the lender. The relative fair value of the common stock was determined to be $125,198, which was recorded as a debt discount and will be amortized over the term of the note using the effective interest rate method.

As of December 31, 2024, the unamortized debt discount was $121,071, and the net carrying amount of the debt was $128,929. Amortization expense related to the debt discount for the period from inception (May 22, 2024) to December 31, 2024 was $4,127 and is included in interest expense in the accompanying statements of operations. The note had an outstanding principal balance of $250,000 as of December 31, 2024 and accrued interest of $1,648, classified as long-term.

As of December 31, 2025, the unamortized debt discount was $20,637, and the net carrying amount of the debt was $229,363. Amortization expense related to the debt discount for the year ended December 31, 2025 was $100,434 and is included in interest expense in the accompanying statements of operations. The note had an outstanding principal balance of $250,000 as of December 31, 2025 and accrued interest of $41,758. The note is currently in default.

**NOTE 4 – CAPITAL STRUCTURE**

The total number of shares of stock which the corporation shall have authority to issue is 110,000,000 shares, of which 100,000,000 shares with zero par value shall be designated as Common Stock and 10,000,000 shares with zero par value shall be designated as Preferred Stock. As of December 31, 2025, the Company had 46,968,550 shares of its common stock issued and outstanding, and on December 31, 2024, the Company had 35,375,500 shares of its common stock issued and outstanding.

The Preferred Stock authorized by the Company's Articles of Incorporation may be issued in one or more series. There have been no preferred shares designated as of December 31, 2025. The Board of Directors of the Corporation is authorized to determine or alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any series and to fix the numbers of shares of any series.

**NOTE 5 – COMMITMENTS AND CONTINGENCIES**

**Legal Matters** – The Company is currently not a defendant in any litigation or threatened litigation that could have a material effect on the Company's financial statements.

**Master Service Agreement** – On December 31, 2024, the Company entered into a one-year agreement that provides access to an AI-powered marketing software and robotic automation capabilities. Consideration for the contract consists of 250,000 shares of the Company's common stock, issued on January 1, 2025, and a monthly fee of $7,500 beginning in April 2025. The Company recognized $250,000 in expense related to lead generation services and $45,000 in expense related to webinar services in connection with this contract during the year ended 2025.

**NOTE 6 – INCOME TAXES**

The Company has established deferred tax assets and liabilities for the recognition of future deductions or taxable amounts and operating loss carry-forwards. Deferred federal and state income tax expense or benefit is recognized as a result of the change in the deferred tax asset or liability during the year using the currently enacted tax laws and rates that apply to the period in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce deferred tax assets to the amount that will more likely than not be realized.

The components of the Company's deferred tax asset and reconciliation of income taxes computed at the statutory rate of 21% - federal, and 5.5% - state, to the income tax amount recorded as of December 31, 2024 and 2025 is as follows:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2025** | **December 31,<br> 2024** |
| Net operating loss | $3376275 | $374365 |
| Tax provision at U.S. federal income tax rate | 21.0% | 21.0% |
| State income tax provision, net of federal | 5.5% | 5.5% |
| Provision for income taxes | 26.5% | 26.5% |
| Deferred tax asset | 894713 | 99207 |
| Valuation allowance | (894713) | (99207) |
| Net deferred tax asset | $- | $- |

---

The Company has not recorded any income tax expense or benefit for the period from inception (May 22, 2024) to December 31, 2025.

At December 31, 2025, the Company had approximately $3,400,000 of unused net operating loss carryforwards. Unused net operating loss carryforwards may provide future benefits although there can be no assurance that these net operating losses will be realized in the future. The tax benefits of these loss carryforwards have been fully offset by valuation allowance. These losses may be used to offset future taxable income and will carryforward indefinitely. The valuation allowance increased by $795,506, from $99,207 as of December 31, 2024 to $894,713 as of December 31, 2025, reflecting the increase in the net deferred tax asset arising from additional net operating losses incurred during the year. The federal and state income tax return for the period from inception (May 22, 2024) through December 31, 2024 has been filed. The federal and state income tax return for the year ended December 31, 2025 has not yet been filed.

**NOTE 7 – RESEARCH AND DEVELOPMENT**

In May 2024, the Company entered into a patent transfer and assignment agreement with the bankruptcy estate of XNK Therapeutics AB ("XNK"), to purchase key patent families and related intellectual property related to a proprietary technology platform and autologous Natural Killer cell therapy drug product. Through a note agreement with a third party discussed in Note 3, Debt, the total consideration paid to XNK was $150,000, which was fully expensed in accordance with ASC 730, *Research and Development*, and is reflected in research and development expense in the accompanying statements of operations for the period from inception (May 22, 2024) to December 31, 2024.

**NOTE 8 – RELATED PARTY TRANSACTIONS**

In May 2024, the Company entered into an unsecured note agreement with a member of its Board of Directors in the principal amount of $150,000. The note is classified as a related party transaction and bears interest at a rate of 6%, with a maturity date of May 28, 2026. A partial principal payment of $100,000 was paid in October 2024. As of December 31, 2024, the remaining principal balance was $50,000 and accrued interest on the note was $4,027. The remaining principal balance and accrued interest was paid during the year ended December 31, 2025.

In September 2024, the Company entered into a subscription agreement with a related-party entity affiliated with a member of the Company's Board of Directors for an aggregate investment of $250,000. The subscription receivable at December 31, 2024 was $150,000. The subscription was fully completed in January 2025.

In and between April 2025 and October 2025, the Company entered into stock subscription agreements with MedTek, LLC for 632,500 shares of common stock at $1.00 per share in private transactions exempt from registration under Regulation D, Rule 506(b) of the Securities Act. Martin Lewis, Director, is a control person of MedTek, LLC.

In November 2025, the Company entered into stock subscription agreements with MedTek, LLC for 1,000,000 shares of common stock at $0.25 per share in a private transaction exempt from registration under Regulation D, Rule 506(b) of the Securities Act. Martin Lewis, Director, is a control person of MedTek, LLC.

**NOTE 9 – SEGMENT REPORTING**

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The Company is operating in one segment, Biotechnology.

Biotechnology Segment: This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $273,934 and $488,327 as of December 31, 2025 and December 31, 2024, respectively.

The Company believes that this structure reflects its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities while maintaining financial discipline. The factors used to identify the Biotechnology operating segment were the difference in future potential revenue streams and customer base, the reporting structure for operational and performance information within the Company, and management's decision to organize the Company around the future potential revenue generating activities of the segment.

Segment information relating the Company's operating segment for the years ended December 31, 2025 and December 31, 2024 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Year Ended <br> December 31, 2025** | **Year Ended <br> December 31, 2025** |
|  | **Biotechnology Segment** | **Total** |
| Sales | $– | $– |
| Total operating expenses | 1990500 | 1990500 |
| Loss from operations | (1990500) | (1990500) |
| Interest expense | (265004) | (265004) |
| Other income | 3594 | 3594 |
| Loss on extinguishment of debt | (841696) | (841696) |
| Change in fair value of put liability | 91696 | 91696 |
| Net loss | $(3001910) | $(3001910) |

---

---

| | | |
|:---|:---|:---|
|  | **Year Ended <br> December 31, 2024** | **Year Ended <br> December 31, 2024** |
|  | **Biotechnology Segment** | **Total** |
| Sales | $– | $&nbsp;&nbsp;&nbsp;&nbsp;– |
| Total operating expenses | 303096 | 303096 |
| Loss from operations | (303096) | &nbsp;&nbsp;&nbsp;&nbsp;(303096) |
| Interest expense | (71269) | (71269) |
| Net loss | $(374365) | $(374365) |

---

**NOTE 10 – SUBSEQUENT EVENTS**

In March 2026, a promissory note with a principal balance of $250,000, originally executed in December 2024, matured and was not repaid. The note bears interest at a fixed rate of 16% per annum. As of the date of these financial statements, the Company has failed to remit payment of the outstanding principal and accrued interest, and the note is currently in default.

**Index to Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 2.1 | [Articles of Incorporation (Incorporated by reference to Exhibit 2.1 to the Company's Offering Statement on Form 1-A (File No. 024-12511) filed on September 26, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024082240/ea021572001ex2-1_noktherap.htm) |
| 2.3 | [Bylaws (Incorporated by reference to Exhibit 2.3 to the Company's Offering Statement on Form 1-A (File No. 024-12511) filed on September 26, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024082240/ea021572001ex2-3_noktherap.htm) |
| 3.1 | [Unsecured Promissory Note in the principal sum of $12,500 of NOK Therapeutics, Inc. as Maker, Dated May 31, 2024 (Incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 1-K (File No. 24R-00991) filed on May 6, 2025](https://www.sec.gov/Archives/edgar/data/2038166/000121390025040030/ea023887301ex3-1_nokther.htm) |
| 3.2 | [Unsecured Promissory Note in the principal sum of $10,000 of NOK Therapeutics, Inc. as Maker, Dated June 28, 2024 (Incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 1-K (File No. 24R-00991) filed on May 6, 2025](https://www.sec.gov/Archives/edgar/data/2038166/000121390025040030/ea023887301ex3-2_nokther.htm) |
| 3.3 | [Unsecured Promissory Note in the principal sum of $250,000 of NOK Therapeutics, Inc. as Maker, Dated December 16, 2024 (Incorporated by reference to Exhibit 3.3 to the Company's Annual Report on Form 1-K (File No. 24R-00991) filed on May 6, 2025](https://www.sec.gov/Archives/edgar/data/2038166/000121390025040030/ea023887301ex3-3_nokther.htm) |
| 4.1 | [Form of Subscription Agreement (Incorporated by reference to Exhibit 4.1 to the Company's Offering Statement on Form 1-A/A (File No. 024-12511) filed on December 09, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024106784/ea022398601ex4-1_noktherap.htm) |
| 6.1 | [Patent Transfer and Assignment Agreement, dated May 23, 2024 (Incorporated by reference to Exhibit 6.1 to the Company's Offering Statement on Form 1-A/A (File No. 024-12511) filed on September 26, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024082240/ea021572001ex6-1_noktherap.htm) |
| 6.2 | [Patent Confirmation Assignment (Incorporated by reference to Exhibit 6.2 to the Company's Offering Statement on Form 1-A/A (File No. 024-12511) filed on September 26, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024082240/ea021572001ex6-2_noktherap.htm) |
| 6.3 | [Unsecured Note dated May 28, 2024 between the Company and GoLabs Research and Development, LLC (Incorporated by reference to Exhibit 6.3 to the Company's Offering Statement on Form 1-A/A (File No. 024-12511) filed on November 26, 2024)](https://www.sec.gov/Archives/edgar/data/2038166/000121390024102942/ea022274501ex6-3_noktherap.htm) |
| 6.4 | [Unsecured Promissory Note in the principal sum of $100,000 of NOK Therapeutics, Inc. as Maker, Dated October 8, 2024 (Incorporated by reference to Exhibit 6.4 to the Company's Annual Report on Form 1-K (File No. 24R-00991) filed on May 6, 2025](https://www.sec.gov/Archives/edgar/data/2038166/000121390025040030/ea023887301ex6-4_nokther.htm) |
| 6.5 | [Unsecured Promissory Note in the principal sum of $250,000 of NOK Therapeutics, Inc. as Maker, Dated November 11, 2024 (Incorporated by reference to Exhibit 6.5 to the Company's Annual Report on Form 1-K (File No. 24R-00991) filed on May 6, 2025](https://www.sec.gov/Archives/edgar/data/2038166/000121390025040030/ea023887301ex6-5_nokther.htm) |
| 6.6 | [Loan Conversion and Put Option Agreement of NOK Therapeutics, Inc., Dated May 29, 2025 (Incorporated by reference to Exhibit 6.6 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-6_nok.htm) |
| 6.7 | [Subscription Agreement in the amount of $50,000, NOK Therapeutics, Inc. as Issuer, Dated April 28, 2025 (Incorporated by reference to Exhibit 6.7 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-7_nok.htm) |
| 6.8 | [Subscription Agreement in the amount of $100,000, NOK Therapeutics, Inc. as Issuer, Dated May 28, 2025 (Incorporated by reference to Exhibit 6.8 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-8_nok.htm) |
| 6.9 | [Subscription Agreement in the amount of $100,000, NOK Therapeutics, Inc. as Issuer, Dated June 27, 2025 (Incorporated by reference to Exhibit 6.9 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-9_nok.htm) |
| 6.10 | [Subscription Agreement in the amount of $100,000, NOK Therapeutics, Inc. as Issuer, Dated July 28, 2025 (Incorporated by reference to Exhibit 6.10 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-10_nok.htm) |
| 6.11 | [Subscription Agreement in the amount of $100,000, NOK Therapeutics, Inc. as Issuer, Dated August 29, 2025 (Incorporated by reference to Exhibit 6.11 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-11_nok.htm) |
| 6.12 | [Subscription Agreement in the amount of $100,000, NOK Therapeutics, Inc. as Issuer, Dated September 26, 2025 (Incorporated by reference to Exhibit 6.12 of the Company's Semi-Annual Report on Form 1-SA (File No. 24R-00991) filed on September 30, 2025)](http://www.sec.gov/Archives/edgar/data/2038166/000121390025093298/ea025911401ex6-12_nok.htm) |
| 6.13\* | [Subscription Agreement in the amount of $82,500, NOK Therapeutics, Inc. as Issuer, Dated October 29, 2025](ea028757101ex6-13.htm) |
| 6.14\* | [Subscription Agreement in the amount of $250,000, NOK Therapeutics, Inc. as Issuer, Dated November 17, 2025](ea028757101ex6-14.htm) |
| 11.1\* | [Consent of Independent Registered Public Accounting Firm.](ea028757101ex11-1.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be filed on its behalf by the undersigned duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NÖK THERAPEUTICS, INC.** | **NÖK THERAPEUTICS, INC.** |
|  | By: | /s/ Robert Lewis |
| Date: April 30, 2026 |  | Robert Lewis |
|  |  | President and Director<br> (Principal Executive Officer) |

---

Pursuant to the requirements of Regulation A, this report has been signed below by the following persons on behalf of the issuer and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Robert Lewis | President and Director | April 30, 2026 |
| Robert Lewis |  |  |
| /s/ Brian Cogley | Director and Chief Financial Officer | April 30, 2026 |
| Brian Cogley |  |  |
| /s/ Martin Lewis | Director | April 30, 2026 |
| Martin Lewis |  |  |

---

## Ex1K-6

**Exhibit 6.13**

**NӦK THERAPEUTICS, INC.**

**$750,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of October 29, 2025 between NӦK Therapeutics, Inc., a Florida corporation ("NӦK" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $750,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of 82,500 Shares from Company at $1 per share for a total purchase amount of $82,500.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

NӦK Therapeutics is a clinical-stage biotechnology company developing Natural Killer (NK) cell-based cancer therapies. These autologous therapies target areas within both hematological malignancies and solid tumors. NӦK is made up of an experienced team that includes renowned NK cell experts. NK cells play an important role in the body's protection against cancer by effectively recognizing virus-infected and tumor cells. NK cells kill both cell types and also interact with other cells making them vital in innate immune defense.

Our proprietary technology platform and autologous NK cell therapy drug product is designed to target cancer, especially in situations where autologous therapies have a clear benefit over allogeneic therapies. Platform enabling selective expansion and activation of NK cells from cancer patient's peripheral blood produces NK cells with increased tumor killing ability.

**<u>Officers, Directors and Advisors</u>**

<u>Robert Lewis – President and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – CFO.</u> Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>Evren Alici M.D., PhD. – Scientific Advisor.</u> Dr. Alici is the Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital.

<u>Hans-Gustaf Ljunggren M.D., PhD. – Scientific Advisor.</u> Professor Ljunggren is the former Dean of Research at Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital and has functioned as Dean of Research at KI.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **NӦK THERAPEUTICS, INC.** | **NӦK THERAPEUTICS, INC.** |
| By: | /s/ Robert Lewis |
|  | Robert Lewis, President |

---

---

| | |
|:---|:---|
| **PURCHASER(S) / AUTHORIZED SIGNER** | **PURCHASER(S) / AUTHORIZED SIGNER** |
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: | 33-2875821 |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777- 1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: __________________________________________ Trust Date: ________________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: <u>______________________________________________________________________________</u>_

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ___________________________________

Address: ______________________________________________________________________________________

## Ex1K-6

**Exhibit 6.14**

**NOK THERAPEUTICS, INC. STOCK PURCHASE AGREEMENT**

This Stock Purchase Agreement ("Agreement") is between NOK Therapeutics, Inc, a Florida corporation ("Company") and MedTek, LLC of 2308 W 5<sup>th</sup> Street Plainview, TX 79072 ("Purchaser"), as of November 17, 2025.

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those shares of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Purchaser agree as follows:

<u>PURCHASE AND SALE</u>

<u>Stock Purchase Amount</u>: Company agrees to sell, and Purchaser agrees to purchase One Million (1,000,000) Shares from Company in exchange for a total purchase price of Two Hundred Fifty Thousand Dollars ($250,000). Purchaser shall deliver to Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Stock Purchase Amount.

<u>Delivery of Shares.</u> As soon as reasonably practicable, Company shall deliver the Shares to Purchaser, in electronic form from the Company's transfer agent.

<u>Tradability of Shares.</u> The Shares, once issued to Purchaser, will be restricted shares as that term is defined under applicable federal and state law, and may not be sold until such time as any restrictive resale periods have expired and then may be sold under the provisions of such governing laws.

<u>MISCELLANEOUS</u>

<u>Accredited Purchaser.</u> Purchaser is a sophisticated and accredited investor as that term is defined under U.S. securities laws and is experienced with investments of the type and nature set forth herein. Purchaser fully understands all risks associated with making an early-stage investment of this type and nature.

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Orange County, Florida.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf' format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf' signature page were an original thereof.

WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

IN WITNESS WHEREOF, the parties hereto have caused this Stock Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | | | |
|:---|:---|:---|:---|
| NOK Therapeutics, Inc. | NOK Therapeutics, Inc. | MedTek, LLC | MedTek, LLC |
| By: | /s/ Robert Lewis | By: | /s/ Jim Bullard |
|  | Robert Lewis, President |  | Jim Bullard, Manager |

---

## Ex1K-11

**Exhibit 11.1**

![](ea028757101_ex11-1img1.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the use in this annual report pursuant to Regulation A on Form 1-K of NÖK Therapeutics, Inc. of our report dated April 30, 2026, relating to our audit of the financial statements of NÖK Therapeutics, Inc. for the year ended December 31, 2025 and for the period from inception (May 22, 2024) to December 31, 2024. We also consent to the reference to us under the caption "Experts" in the Form 1-K.

![](ea028757101_ex11-1img2.jpg)

Tampa, Florida

April 30, 2026

**3702 W Spruce St #1430 ● Tampa, Florida 33607 ● +1.813.441.9707**

## Form 1-K Filing Summary

### Filer Information

**Issuer CIK:** 0002038166

**Issuer CCC:** XXXXXXXX

**Is filer a shell company?:** No

**Is this filing by a successor company?:** No

### Submission Contact Information

**Is this a LIVE or TEST Filing?:** LIVE

**Period:** 12-31-2025

### Item 1: Issuer Information (Tab 1 Notification)

**Type of Report:** Annual Report

**Fiscal Year End:** 12-31-2025

**Exact Name of Issuer:** NOK Therapeutics, Inc.

**CIK:** 0002038166

**Jurisdiction of Incorporation:** FL

**IRS Number:** 99-3344253

**Address:** 2009 Mackenzie Way, Cranberry Twp, PA 16066

**Issuer Phone Number:** 888-691-5839

**Title of each class of securities issued pursuant to Regulation A:** Class A Common

### Item 2: Ongoing Reporting Requirements

**Is the issuer relying on the relief provided by Rule 257(d) for this filing?** Yes